CLENPIQ- sodium picosulfate, magnesium oxide, and anhydrous citric acid liquid
ASM Aerosol-Service AG

HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use CLENPIQ™ safely and effectively. See full prescribing information for CLENPIQ.

CLENPIQ™ (sodium picosulfate, magnesium oxide, and anhydrous citric acid) oral solution
Initial U.S. Approval: 2012

INDICATIONS AND USAGE
CLENPIQ™ is a combination of sodium picosulfate, a stimulant laxative, and magnesium oxide and anhydrous citric acid, which form magnesium citrate, an osmotic laxative, indicated for cleansing of the colon as a preparation for colonoscopy in adults. (1)

DOSAGE AND ADMINISTRATION
Administration:
- CLENPIQ is ready to drink. It does not need to be diluted prior to administration. One bottle of CLENPIQ is equivalent to one dose. (2.1)
- Two doses of CLENPIQ are required for a complete preparation for colonoscopy. The preferred method is the "Split-Dose" method. The alternative is the "Day Before" method. (2.1)
- Additional fluids must be consumed after every dose of CLENPIQ in both dosing regimens. (2.1, 5.1)
- Do not take oral medications within 1 hour of start of each dose. (2.1, 7.2)
- If taking tetracycline or fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, or penicillamine, take these medications at least 2 hours before and not less than 6 hours after administration of CLENPIQ. (2.1, 7.3)
- For complete information on preparation before colonoscopy and administration of the dosage regimen, see full prescribing information. (2.1, 2.2, 2.3)

Split-Dose Dosage Regimen (Preferred Method) (2.2)
- First dose: administer during evening before the colonoscopy
- Second dose: administer the next day, during the morning prior to the colonoscopy.

Day-Before Dosage Regimen (Alternative Method), if Split-Dosing is inappropriate (2.3)
- First dose: administer during afternoon or early evening before the colonoscopy.
- Second dose: administer 6 hours later during evening before colonoscopy.

DOSAGE FORMS AND STRENGTHS
CLENPIQ oral solution: Each bottle contains 10 mg of sodium picosulfate, 3.5 g of magnesium oxide, and 12 g of anhydrous citric acid in 160 mL of solution (3)

CONTRAINDICATIONS
- Patients with severely reduced renal function (creatinine clearance less than 30 mL/minute) (4, 5.3, 8.6)
- Gastrointestinal (GI) obstruction or ileus (4)
- Bowel perforation (4)
- Toxic colitis or toxic megacolon (4)
- Gastric retention (4)
- An allergy to any of the ingredients in CLENPIQ (4)

WARNINGS AND PRECAUTIONS
- Risk of fluid and electrolyte abnormalities, arrhythmia, seizures, and renal impairment: Encourage adequate hydration, assess concurrent medications, and consider laboratory assessments prior to and after use. (5.1, 5.2, 5.3, 5.4, 7.1)
- Use in patients with renal impairment or taking concomitant medications that affect renal function: Use caution, ensure adequate hydration, and consider testing. (4, 5.3, 7.1)
- Mucosal ulcerations: Consider potential for mucosal ulcerations when interpreting colonoscopy findings in patients with known or suspected inflammatory bowel disease. (5.5)
- Suspected GI obstruction or perforation: Rule out diagnosis before administration. (4, 5.6)
- Patients at risk for aspiration: Observe during administration. (5.7)

ADVERSE REACTIONS
Most common adverse reactions (>1%) are nausea, headache, and vomiting. (6.1)
FULL PRESCRIBING INFORMATION: CONTENTS*
1 INDICATIONS AND USAGE
2 DOSAGE AND ADMINISTRATION
   2.1 Important Administration Instructions
   2.2 Split-Dose Dosage Regimen (Preferred Method)
   2.3 Day-Before Dosage Regimen (Alternative Method)
3 DOSAGE FORMS AND STRENGTHS
4 CONTRAINDICATIONS
5 WARNINGS AND PRECAUTIONS
   5.1 Serious Fluid and Serum Chemistry Abnormalities
   5.2 Seizures
   5.3 Use in Patients with Renal Impairment
   5.4 Cardiac Arrhythmias
   5.5 Colonic Mucosal Ulceration, Ischemic Colitis, and Ulcerative Colitis
   5.6 Use in Patients with Significant Gastrointestinal Disease
   5.7 Aspiration
6 ADVERSE REACTIONS
   6.1 Clinical Trials Experience
   6.2 Postmarketing Experience
7 DRUG INTERACTIONS
   7.1 Drugs That May Increase Risks of Fluid and Electrolyte Abnormalities
   7.2 Potential for Reduced Drug Absorption
   7.3 Antibiotics
8 USE IN SPECIFIC POPULATIONS
   8.1 Pregnancy
   8.2 Lactation
   8.4 Pediatric Use
   8.5 Geriatric Use
   8.6 Renal Impairment
10 OVERDOSAGE
11 DESCRIPTION
12 CLINICAL PHARMACOLOGY
   12.1 Mechanism of Action
   12.2 Pharmacodynamics
   12.3 Pharmacokinetics
13 NONCLINICAL TOXICOLOGY
   13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
14 CLINICAL STUDIES
16 HOW SUPPLIED/STORAGE AND HANDLING
17 PATIENT COUNSELING INFORMATION
* Sections or subsections omitted from the full prescribing information are not listed.
FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE
CLENPIQ is indicated for cleansing of the colon as a preparation for colonoscopy in adults.

2 DOSAGE AND ADMINISTRATION

2.1 Important Administration Instructions
- Correct fluid and electrolyte abnormalities before administration of CLENPIQ.
- CLENPIQ is ready to drink. It does not need to be diluted prior to administration. One bottle of CLENPIQ is equivalent to one dose.
- Two doses of CLENPIQ are required for a complete preparation for colonoscopy either as a Split-Dose (preferred) or Day-Before dosing regimen.
- The preferred method is the "Split-Dose" method and consists of two separate doses: the first dose during the evening before the colonoscopy and the second dose the next day, during the morning prior to the colonoscopy [see Dosage and Administration (2.2)].
- The alternative method is the "Day Before" method and consists of two separate doses: the first dose during the afternoon or early evening before the colonoscopy and the second dose 6 hours later during the evening before the colonoscopy [see Dosage and Administration (2.3)].
- Additional fluids must be consumed after every dose of CLENPIQ in both dosing regimens [see Dosage and Administration (2.2) and Warnings and Precautions (5.1)].
- Consume only clear fluids (no solid food) from the start of CLENPIQ treatment until after the colonoscopy.
- Do not eat solid food or dairy and do not drink anything colored red or purple.
- Do not drink alcohol.
- Do not take other laxatives while taking CLENPIQ
- Do not take oral medications within one hour of starting CLENPIQ.
- If taking tetracycline or fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, or penicillamine, take these medications at least 2 hours before and not less than 6 hours after administration of CLENPIQ.
- Stop consumption of all fluids at least 2 hours before the colonoscopy.

2.2 Split-Dose Dosage Regimen (Preferred Method)
The Split-Dose regimen is the preferred dosing method. Instruct patients to take two separate doses in conjunction with fluids, as follows:

Dose 1 – On the day before colonoscopy:
- Instruct patients to consume only clear liquids (no solid food or dairy) on the day before the colonoscopy up until 2 hours before the time of the colonoscopy.
- Take the first dose (1 bottle) of CLENPIQ during the evening before the colonoscopy (e.g., 5:00 to 9:00 PM).
- Follow CLENPIQ by drinking five 8-ounce cups (cup provided) of clear liquids (40 ounces total) within 5 hours and before bed.
- If severe bloating, distention, or abdominal pain occurs, following the first dose, delay the second dose until the symptoms resolve.

Dose 2 – Next morning on the day of colonoscopy (start approximately 5 hours prior to colonoscopy):
- Continue to consume only clear liquids (no solid food or dairy).
- Take the second dose (the second bottle) of CLENPIQ.
• Following the CLENPIQ dose, drink at least three 8-ounce cups (cup provided) of clear liquids (24 ounces) at least 2 hours before the colonoscopy.

2.3 Day-Before Dosage Regimen (Alternative Method)
The Day-Before regimen is the alternative dosing method for patients for whom the Split-Dosing is inappropriate. Instruct patients to take two separate doses in conjunction with fluids, as follows:

Dose 1 – On the day before colonoscopy:
• Instruct patients to consume only clear liquids (no solid food or dairy) on the day before the colonoscopy up until 2 hours before the time of the colonoscopy.
• Take the first dose (1 bottle) of CLENPIQ in the afternoon or early evening before the colonoscopy (e.g., 4:00 to 6:00 PM).
• Following the CLENPIQ dose, drink five 8-ounce cups (cup provided) of clear liquids (40 ounces total) within 5 hours and before the next dose.
• If severe bloating, distention, or abdominal pain occurs, following the first dose, delay the second dose until the symptoms resolve.

Dose 2 – Approximately 6 hours later in the evening the night before the colonoscopy (e.g., 10:00 PM to 12:00 AM):
• Take the second dose (the second bottle) of CLENPIQ.
• Following the CLENPIQ dose, drink three 8-ounce cups (cup provided) (24 ounces) of clear liquids within 5 hours and before bed.

3 DOSAGE FORMS AND STRENGTHS
Oral solution: Each bottle contains 10 mg of sodium picosulfate, 3.5 grams of magnesium oxide, and 12 grams of anhydrous citric acid in 160 mL of colorless to slightly yellow, clear solution.

4 CONTRAINDICATIONS
CLENPIQ is contraindicated in the following conditions:
• Patients with severe renal impairment (creatinine clearance less than 30 mL/minute), which may result in accumulation of magnesium [see Warnings and Precautions (5.3)]
• Gastrointestinal obstruction or ileus [see Warnings and Precautions (5.6)]
• Bowel perforation [see Warnings and Precautions (5.6)]
• Toxic colitis or toxic megacolon
• Gastric retention
• Hypersensitivity to any of the ingredients in CLENPIQ

5 WARNINGS AND PRECAUTIONS
5.1 Serious Fluid and Serum Chemistry Abnormalities
Advise patients to hydrate adequately before, during, and after the use of CLENPIQ. Use caution in patients with congestive heart failure when replacing fluids. If a patient develops significant vomiting or signs of dehydration including signs of orthostatic hypotension after taking CLENPIQ, consider performing post-colonoscopy lab tests (electrolytes, creatinine, and BUN) and treat accordingly. Approximately 20% of patients in both arms (sodium picosulfate, magnesium oxide, and anhydrous citric acid, 2 L of PEG + E plus two × 5-mg bisacodyl tablets) of clinical trials of another oral formulation of sodium picosulfate, magnesium oxide, and anhydrous citric acid had orthostatic changes in blood pressure and/or heart rate on the day of colonoscopy and up to seven days post colonoscopy [see Adverse Reactions (6.1)].
Fluid and electrolyte disturbances can lead to serious adverse reactions including cardiac arrhythmias or seizures and renal impairment. Correct fluid and electrolyte abnormalities before treatment with CLENPIQ. In addition, use caution when prescribing CLENPIQ for patients who have conditions or who are using medications that increase the risk for fluid and electrolyte disturbances or that may increase the risk of seizure, arrhythmia, and renal impairment [see Drug Interactions (7.1)].

5.2 Seizures

There have been reports of generalized tonic-clonic seizures with the use of bowel preparation products in patients with no prior history of seizures. The seizure cases were associated with electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, and hypomagnesemia) and low serum osmolality. The neurologic abnormalities resolved with correction of fluid and electrolyte abnormalities.

Use caution when prescribing CLENPIQ for patients with a history of seizures and in patients at risk of seizure, such as patients taking medications that lower the seizure threshold (e.g., tricyclic antidepressants), patients withdrawing from alcohol or benzodiazepines, patients with known or suspected hyponatremia [see Adverse Reactions (6.2)].

5.3 Use in Patients with Renal Impairment

As with other magnesium containing bowel preparations, use caution when prescribing CLENPIQ for patients with impaired renal function or patients taking concomitant medications that may affect renal function (such as diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or non-steroidal anti-inflammatory drugs) [see Drug Interactions (7.1)]. These patients may be at increased risk for renal injury. Advise these patients of the importance of adequate hydration before, during, and after the use of CLENPIQ. Consider performing baseline and post-colonoscopy laboratory tests (electrolytes, creatinine, and BUN) in these patients. CLENPIQ is contraindicated in patients with severe renal impairment (creatinine clearance less than 30 mL/min), as accumulation of magnesium in plasma may occur [see Contraindications (4)].

5.4 Cardiac Arrhythmias

There have been rare reports of serious arrhythmias associated with the use of ionic osmotic laxatives for bowel preparation. Use caution when prescribing CLENPIQ for patients at increased risk of arrhythmias (e.g., patients with a history of prolonged QT, uncontrolled arrhythmias, recent myocardial infarction, unstable angina, congestive heart failure, or cardiomyopathy). Consider pre-dose and post-colonoscopy ECGs in patients at increased risk of serious cardiac arrhythmias.

5.5 Colonic Mucosal Ulceration, Ischemic Colitis, and Ulcerative Colitis

Osmotic laxatives may produce colonic mucosal aphthous ulcerations and there have been reports of more serious cases of ischemic colitis requiring hospitalization. Concurrent use of additional stimulant laxatives with CLENPIQ may increase this risk. Consider the potential for mucosal ulcerations when interpreting colonoscopy findings in patients with known or suspected inflammatory bowel disease [see Adverse Reactions (6.2)].

5.6 Use in Patients with Significant Gastrointestinal Disease

If gastrointestinal obstruction or perforation is suspected, perform appropriate diagnostic studies to rule out these conditions before administering CLENPIQ [see Contraindications (4)]. Use with caution in patients with severe active ulcerative colitis.

5.7 Aspiration

Patients with impaired gag reflex are at risk for regurgitation or aspiration during the administration of CLENPIQ. Observe these patients during the administration of CLENPIQ. Use with caution in these patients.
Observe patients with impaired gag reflex and patients prone to regurgitation or aspiration during the administration of CLENPIQ. Use with caution in these patients.

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in practice.

The safety of CLENPIQ has been established from adequate and well-controlled trials of another orally administered formulation of sodium picosulfate, magnesium oxide and anhydrous citric acid [see Clinical Studies (14)]. Adverse reactions reported in these adequate and well-controlled studies are described below.

In two randomized, multicenter, investigator-blinded, active-controlled clinical trials for colon cleansing, another oral formulation of sodium picosulfate, magnesium oxide, and anhydrous citric acid was compared with a regimen of two liters (2 L) of polyethylene glycol plus electrolytes solution (PEG + E) and two 5-mg bisacodyl tablets, all administered the day before the procedure [see Clinical Studies (14)]. Patients were not blinded to study treatment. Table 1 displays the most common adverse reactions for the Split-Dose and Day-Before dosing regimens in Studies 1 and Study 2, respectively.

Since abdominal bloating, distension, pain/cramping, and watery diarrhea are known to occur in response to colon cleansing preparations, these effects were documented as adverse reactions in the clinical trials only if they required medical intervention (such as a change in study drug or led to study discontinuation, therapeutic or diagnostic procedures, met the criteria for a serious adverse reaction), or showed clinically significant worsening during the study that was not in the frame of the usual clinical course, as determined by the investigator.

Table 1: Common Adverse Reactions* observed in at Least 1% of Patients using the Split-Dose Regimen or Day-Before Regimen for Colon Cleansing*

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>Study 1: Split-Dose Regimen</th>
<th>Study 2: Day-Before Regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium picosulfate, magnesium oxide, and anhydrous citric acid (N=305) n (% = n/N)</td>
<td>2 L PEG+E† with 2 × 5-mg bisacodyl tablets (N=298) n (% = n/N)</td>
<td>Sodium picosulfate, magnesium oxide, and anhydrous citric acid (N=296) n (% = n/N)</td>
</tr>
<tr>
<td>Nausea</td>
<td>8 (3)</td>
<td>11 (4)</td>
</tr>
<tr>
<td>Headache</td>
<td>5 (2)</td>
<td>5 (2)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>3 (1)</td>
<td>10 (3)</td>
</tr>
</tbody>
</table>

* abdominal bloating, distension, pain/cramping, and watery diarrhea not requiring an intervention were not collected
† 2 L PEG + E = two liters polyethylene glycol plus electrolytes solution.

Electrolyte Abnormalities

In general, sodium picosulfate, magnesium oxide, and anhydrous citric acid was associated with numerically higher rates of abnormal electrolyte shifts on the day of colonoscopy compared to the control regimen (Table 2). These shifts were transient in nature and numerically similar between treatment arms at the Day 30 visit.
Table 2: Shifts from Normal Baseline to Outside the Normal Range at Day 7 and Day 30

<table>
<thead>
<tr>
<th>Laboratory Parameter (direction of change)</th>
<th>Visit</th>
<th>Study 1: Split-Dose Regimen</th>
<th>Study 2: Day-Before Regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Sodium picosulfate, magnesium oxide, and anhydrous citric acid</td>
<td>Sodium picosulfate, magnesium oxide, and anhydrous citric acid</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2 L PEG+E with 2× 5 mg bisacodyl tablets</td>
<td>2 L PEG+E with 2× 5 mg bisacodyl tablets</td>
</tr>
<tr>
<td></td>
<td></td>
<td>N/N (%)</td>
<td>N/N (%)</td>
</tr>
<tr>
<td>Potassium (low)</td>
<td>Day of Colonoscopy</td>
<td>19/260 (7.3)</td>
<td>13/274 (4.7)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3/302 (1.0)</td>
<td>5/292 (1.7)</td>
</tr>
<tr>
<td></td>
<td>24-48 hours</td>
<td>1/295 (0.3)</td>
<td>2/295 (0.7)</td>
</tr>
<tr>
<td></td>
<td>Day 7</td>
<td>8/279 (2.9)</td>
<td>6/276 (2.2)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7/275 (2.5)</td>
<td>8/284 (2.8)</td>
</tr>
<tr>
<td></td>
<td>Day 30</td>
<td>8/278 (2.9)</td>
<td>6/276 (2.2)</td>
</tr>
<tr>
<td>Sodium (low)</td>
<td>Day of Colonoscopy</td>
<td>11/298 (3.7)</td>
<td>3/286 (1.0)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1/303 (0.3)</td>
<td>1/293 (0.3)</td>
</tr>
<tr>
<td></td>
<td>24-48 hours</td>
<td>1/295 (0.3)</td>
<td>2/295 (0.7)</td>
</tr>
<tr>
<td></td>
<td>Day 7</td>
<td>1/292 (0.3)</td>
<td>1/292 (0.3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1/285 (0.3)</td>
<td>1/291 (0.3)</td>
</tr>
<tr>
<td></td>
<td>Day 30</td>
<td>3/291 (1.0)</td>
<td>1/284 (0.4)</td>
</tr>
<tr>
<td>Chloride (low)</td>
<td>Day of Colonoscopy</td>
<td>11/301 (3.7)</td>
<td>3/287 (1.0)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1/292 (0.3)</td>
<td>2/288 (0.7)</td>
</tr>
<tr>
<td></td>
<td>24-48 hours</td>
<td>1/295 (0.0)</td>
<td>0/293 (0.0)</td>
</tr>
<tr>
<td></td>
<td>Day 7</td>
<td>3/295 (1.0)</td>
<td>0/293 (0.0)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0/285 (0.0)</td>
<td>0/293 (0.0)</td>
</tr>
<tr>
<td></td>
<td>Day 30</td>
<td>3/294 (1.0)</td>
<td>0/298 (0.0)</td>
</tr>
<tr>
<td>Magnesium (high)</td>
<td>Day of Colonoscopy</td>
<td>34/294 (11.6)</td>
<td>25/288 (8.7)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0/294 (0.0)</td>
<td>1/289 (0.3)</td>
</tr>
<tr>
<td></td>
<td>24-48 hours</td>
<td>0/303 (0.0)</td>
<td>0/295 (0.0)</td>
</tr>
<tr>
<td></td>
<td>Day 7</td>
<td>0/297 (0.0)</td>
<td>0/288 (0.0)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1/291 (0.3)</td>
<td>1/286 (0.3)</td>
</tr>
<tr>
<td></td>
<td>Day 30</td>
<td>2/290 (0.7)</td>
<td>0/286 (0.0)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0/286 (0.0)</td>
<td>0/290 (0.0)</td>
</tr>
<tr>
<td>Calcium (low)</td>
<td>Day of Colonoscopy</td>
<td>2/292 (0.7)</td>
<td>0/276 (0.0)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1/286 (0.3)</td>
<td>2/282 (0.7)</td>
</tr>
<tr>
<td></td>
<td>24-48 hours</td>
<td>0/303 (0.0)</td>
<td>0/295 (0.0)</td>
</tr>
<tr>
<td></td>
<td>Day 7</td>
<td>0/293 (0.0)</td>
<td>0/274 (0.0)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1/283 (0.4)</td>
<td>0/278 (0.0)</td>
</tr>
<tr>
<td></td>
<td>Day 30</td>
<td>0/292 (0.0)</td>
<td>1/282 (0.4)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0/274 (0.0)</td>
<td>1/283 (0.4)</td>
</tr>
<tr>
<td>Creatinine (high)</td>
<td>Day of Colonoscopy</td>
<td>5/260 (1.9)</td>
<td>13/268 (4.9)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0/295 (0.0)</td>
<td>12/266 (4.5)</td>
</tr>
<tr>
<td></td>
<td>24-48 hours</td>
<td>1/303 (0.3)</td>
<td>0/288 (0.0)</td>
</tr>
<tr>
<td></td>
<td>Day 7</td>
<td>13/267 (4.8)</td>
<td>10/264 (3.8)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>10/264 (3.8)</td>
<td>10/265 (3.8)</td>
</tr>
<tr>
<td></td>
<td>Day 30</td>
<td>11/264 (4.2)</td>
<td>18/264 (6.8)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>14/265 (5.3)</td>
<td>10/272 (3.7)</td>
</tr>
<tr>
<td>eGFR (low)</td>
<td>Day of Colonoscopy</td>
<td>22/221 (10.0)</td>
<td>26/199 (13.1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>17/214 (7.9)</td>
<td>25/224 (11.2)</td>
</tr>
<tr>
<td></td>
<td>24-48 hours</td>
<td>76/303 (25.1)</td>
<td>82/288 (28.5)</td>
</tr>
<tr>
<td></td>
<td>Day 7</td>
<td>72/295 (24.4)</td>
<td>62/293 (21.2)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>17/213 (8.0)</td>
<td>11/198 (5.6)</td>
</tr>
<tr>
<td></td>
<td>Day 30</td>
<td>24/223 (10.8)</td>
<td>28/219 (12.8)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>21/211 (10.0)</td>
<td>24/224 (10.7)</td>
</tr>
</tbody>
</table>

eGFR = estimated glomerular filtration rate

6.2 Postmarketing Experience

The following adverse reactions have been identified during post approval use of another oral formulation of sodium picosulfate (10 mg), magnesium oxide (3.5 mg) and anhydrous citric acid (12 g).
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

**Hypersensitivity:** rash, urticaria, and purpura

**Gastrointestinal:** abdominal pain, diarrhea, fecal incontinence, proctalgia, reversible aphthoid ileal ulcers, ischemic colitis [see Warnings and Precautions (5.5)]

**Neurologic:** generalized tonic-clonic seizures with and without hyponatremia in epileptic patients [see Warnings and Precautions (5.2)].

### 7 DRUG INTERACTIONS

#### 7.1 Drugs That May Increase Risks of Fluid and Electrolyte Abnormalities

Use caution when prescribing CLENPIQ for patients with conditions or who are taking other drugs that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias or QT prolongation in the setting of fluid and electrolyte abnormalities. [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)].

#### 7.2 Potential for Reduced Drug Absorption

CLENPIQ can reduce the absorption of other co-administered drugs [see Dosage and Administration (2.1)]:

- Administer oral medications at least one hour before the start of administration of CLENPIQ.
- Administer tetracycline and fluoroquinolone antibiotics [see Drug Interactions (7.3)], iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of CLENPIQ to avoid chelation with magnesium.

#### 7.3 Antibiotics

Prior or concomitant use of antibiotics with CLENPIQ may reduce efficacy of CLENPIQ as conversion of sodium picosulfate to its active metabolite BHPM is mediated by colonic bacteria.

### 8 USE IN SPECIFIC POPULATIONS

#### 8.1 Pregnancy

**Risk Summary**

There are no data with CLENPIQ use in pregnant women to determine a drug-associated risk of adverse developmental outcomes. In animal reproduction studies, no adverse developmental effects were observed in pregnant rats when sodium picosulfate, magnesium oxide, and anhydrous citric acid were administered orally at doses 1.2 times the recommended human dose based on body surface area during organogenesis.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

**Data**

**Animal Data**

Reproduction studies with sodium picosulfate, magnesium oxide, and anhydrous citric acid have been performed in pregnant rats following oral administration of up to 2000 mg/kg twice daily (about 1.2 times the recommended human dose based on body surface area) during the period of organogenesis. There was no evidence of harm to the fetus due to sodium picosulfate, magnesium oxide, and anhydrous
citric acid. The reproduction study in rabbits was not adequate, as treatment-related mortalities were observed at all doses. A pre and postnatal development study with sodium picosulfate, magnesium oxide, and anhydrous citric acid in rats showed no evidence of any adverse effect on pre and postnatal development at oral doses up to 2000 mg/kg twice daily (about 1.2 times the recommended human dose based on body surface area).

Published reproduction studies with sodium picosulfate in pregnant rats and rabbits during the period of organogenesis did not show evidence of harm to the fetus at doses up to 100 mg/kg (approximately 49 and 98 times, respectively, the recommended human dose of 10 mg sodium picosulfate based on body surface area).

8.2 Lactation

Risk Summary

There are no data on the presence of magnesium oxide or anhydrous citric acid in either human or animal milk, the effects on the breastfed infant, or the effects on milk production. Published data on lactating women indicate that the active metabolite of sodium picosulfate, bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM) remained below the limit of detection (1 ng/mL) in breast milk after both single and multiple doses of 10 mg/day. There are no data on the effects of sodium picosulfate on the breastfed infant or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for CLENPIQ and any potential adverse effects on the breastfed infant from CLENPIQ or the underlying maternal condition.

8.4 Pediatric Use

The safety and effectiveness of CLENPIQ in pediatric patients have not been established.

8.5 Geriatric Use

Of the 1201 patients in clinical trials who received another formulation of sodium picosulfate, magnesium oxide, and anhydrous citric acid, 215 (18%) patients were 65 years of age or older. No overall differences in safety or effectiveness were observed between geriatric patients and younger patients.

8.6 Renal Impairment

CLENPIQ is contraindicated in patients with severe renal impairment (creatinine clearance less than 30 mL/min), as accumulation of magnesium in plasma may occur [see Contraindications (4)]. Patients with less severe renal impairment or patients taking concomitant medications that may affect renal function may be at increased risk for renal injury [see Warnings and Precautions (5.3)]. Advise these patients of the importance of adequate hydration before, during, and after the use of CLENPIQ [see Dosage and Administration (2.1)]. Consider performing baseline and post-colonoscopy laboratory tests (electrolytes, creatinine, and BUN) in these patients.

10 OVERDOSAGE

Overdosage of more than the recommended dose of CLENPIQ may lead to severe electrolyte disturbances, as well as dehydration and hypovolemia, with signs and symptoms of these disturbances [see Warnings and Precautions (5.1)]. Monitor for fluid and electrolyte disturbances and treat symptomatically.

11 DESCRIPTION

CLENPIQ (sodium picosulfate, magnesium oxide, and anhydrous citric acid) oral solution is a stimulant and osmotic laxative that is provided as a cranberry-flavored, colorless to slightly yellow, clear oral solution, and is supplied as two bottles in each carton.
Each bottle of CLENPIQ contains 10 mg sodium picosulfate, USP; 3.5 g magnesium oxide, USP; and 12 g anhydrous citric acid, USP. The product also contains the following inactive ingredients:

acesulfame potassium, cranberry flavor, disodium edetate, malic acid, sodium benzoate, sodium hydroxide, sodium metabisulfite, sucralose, and water. The cranberry flavor contains glycercyl triacetate (triacetin), maltodextrin and sodium octenyl succinated starch.

The following is a description of the three active ingredients contained in CLENPIQ:

**Sodium Picosulfate**
- Chemical name: 4,4’-(2-pyridylmethylene) diphenyl bis(hydrogen sulfate) disodium salt, monohydrate
- Chemical formula: C_{18}H_{13}NNa_{2}O_{8}S_{2}·H_{2}O
- Molecular weight: 499.4
- Structural formula:

![Sodium Picosulfate structure](image1)

**Magnesium Oxide**
- Chemical name: Magnesium oxide
- Chemical formula: MgO
- Molecular weight: 40.3
- Structural formula: MgO

**Anhydrous Citric Acid**
- Chemical name: 2-hydroxypropane-1,2,3-tricarboxylic acid
- Chemical formula: C_{6}H_{8}O_{7}
- Molecular weight: 192.1
- Structural formula:

![Anhydrous Citric Acid structure](image2)

**12 CLINICAL PHARMACOLOGY**

**12.1 Mechanism of Action**
Sodium picosulfate is hydrolyzed by colonic bacteria to form an active metabolite: bis-(p-hydroxyphenyl)-pyridyl-2-methane, BHPM, which acts directly on the colonic mucosa to stimulate colonic
peristalsis. Magnesium oxide and citric acid react to create magnesium citrate in solution, which is an osmotic agent that causes water to be retained within the gastrointestinal tract.

12.2 Pharmacodynamics
The stimulant laxative activity of sodium picosulfate together with the osmotic laxative activity of magnesium citrate produces a purgative effect which, when ingested with additional fluids, produces watery diarrhea.

12.3 Pharmacokinetics

Absorption
Sodium picosulfate, which is a prodrug, is converted to its active metabolite, BHPM, by colonic bacteria. After administration of two doses of sodium picosulfate, magnesium oxide, and anhydrous citric acid separated by 6 hours in 16 healthy subjects, sodium picosulfate reached a mean $C_{\text{max}}$ of 3.2 ng/mL at approximately 7 hours ($T_{\text{max}}$). After the first dose, the corresponding values were 2.3 ng/mL at 2 hours. The terminal half-life of sodium picosulfate was 7.4 hours.

Elimination
Metabolism and Excretion
The fraction of the absorbed sodium picosulfate dose excreted unchanged in urine was 0.19%. Plasma levels of the free BHPM were low, with 13 out of 16 subjects studied having plasma BHPM concentrations below the lower limit of quantification (0.1 ng/mL). Urinary samples show that the majority of excreted BHPM was in the glucuronide-conjugated form. Magnesium oxide and citric acid react in water to create magnesium citrate. Baseline uncorrected magnesium concentration reached a maximum ($C_{\text{max}}$) of approximately 1.9 mEq/L, which occurred at 10 hours post initial dose administration ($T_{\text{max}}$). This represents an approximately 20% increase from the baseline.

Drug Interaction Studies
In an in vitro study using human liver microsomes, sodium picosulfate did not inhibit the major CYP enzymes (CYP 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4/5) evaluated. Based on an in vitro study using freshly isolated hepatocyte culture, sodium picosulfate is not an inducer of CYP1A2, CYP2B6, or CYP3A4/5.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
Long-term studies in animals to evaluate carcinogenic potential or studies to evaluate mutagenic potential have not been performed with CLENPIQ.

Sodium picosulfate was not mutagenic in the Ames test, the mouse lymphoma assay, and the mouse bone marrow micronucleus test.

In an oral fertility study in rats, sodium picosulfate, magnesium oxide, and anhydrous citric acid did not cause any significant adverse effect on male or female fertility parameters up to a maximum dose of 2000 mg/kg twice daily (about 1.2 times the recommended human dose based on body surface area).

14 CLINICAL STUDIES
The safety and efficacy of CLENPIQ has been established based on adequate and well-controlled studies of another oral formulation of sodium picosulfate, magnesium oxide and anhydrous citric acid. Below is a description of the results of these two adequate and well-controlled studies.

The colon-cleansing efficacy of sodium picosulfate, magnesium oxide, and anhydrous citric acid was
evaluated for non-inferiority against a comparator in two randomized, investigator-blinded, active-controlled, multicenter US trials in patients scheduled to have an elective colonoscopy. In all, 1195 adult patients were included in the primary efficacy analysis: 601 from Study 1 and 594 from Study 2. Patients ranged in age from 18 to 80 years (mean age 56 years); 61% were female and 39% male. Self-identified race was distributed as follows: 90% White, 10% Black, and less than 1% other. Of these, 3% self-identified their ethnicity as Hispanic or Latino.

Patients randomized to the sodium picosulfate, magnesium oxide, and anhydrous citric acid group in the two studies were treated with one of two dosing regimens:

- In Study 1, sodium picosulfate, magnesium oxide, and anhydrous citric acid were given by "Split-Dose" (evening before and day of) dosing, where the first dose was taken the evening before the colonoscopy (between 5:00 and 9:00 PM), followed by five (5) 8-ounce glasses of clear liquid, and the second dose was taken the morning of the colonoscopy (at least 5 hours prior to but no more than 9 hours prior to colonoscopy), followed by three (3) 8-ounce glasses of clear liquid.
- In Study 2, sodium picosulfate, magnesium oxide, and anhydrous citric acid were given by "Day-Before" (afternoon/evening before only) dosing, where both doses were taken separately on the day before the colonoscopy, with the first dose taken in the afternoon (between 4:00 and 6:00 PM), followed by five (5) 8-ounce glasses of clear liquid, and the second dose taken in the late evening (approximately 6 hours later, between 10:00 PM and 12:00 AM), followed by three (3) 8-ounce glasses of clear liquid.

The comparator was a preparation containing two liters of polyethylene glycol plus electrolytes solution (PEG + E) and two 5-mg bisacodyl tablets, administered the day before the procedure. All patients in both treatment groups were limited to a clear liquid diet on the day before the procedure (24 hours before).

The primary efficacy endpoint was the proportion of patients with successful colon cleansing, as assessed by blinded colonoscopists using the Aronchick Scale. The Aronchick scale is a tool used to assess overall colon cleansing. Successful colon cleansing was defined as bowel preparations with >90% of the mucosa seen and mostly liquid stool that were graded excellent (minimal suctioning needed for adequate visualization) or good (significant suctioning needed for adequate visualization) by the colonoscopist.

In both studies, the sodium picosulfate, magnesium oxide, and anhydrous citric acid combination was non-inferior to the comparator. In addition, sodium picosulfate, magnesium oxide, and anhydrous citric acid provided by Split-Dose dosing met the pre-specified criteria for superiority to the comparator for colon cleansing in Study 1. The comparator in that study was administered entirely on the day prior to colonoscopy. See Tables 3 and 4 below.

<table>
<thead>
<tr>
<th>Sodium picosulfate, magnesium oxide, and anhydrous citric acid</th>
<th>2 L PEG+E* with 2 × 5-mg bisacodyl tablets</th>
<th>Difference between treatment groups</th>
</tr>
</thead>
<tbody>
<tr>
<td>Split-Dose Regimen</td>
<td>% (n/N)</td>
<td>% (n/N)</td>
</tr>
<tr>
<td>84% (256/304)</td>
<td>74% (221/297)</td>
<td>10%</td>
</tr>
</tbody>
</table>

* 2 L PEG + E = two liters polyethylene glycol plus electrolytes solution.
† Non-inferior and superior 2 L PEG+E with 2 × 5-mg bisacodyl tablets
Table 4: Proportion of Patients with Successful Colon Cleansing in Study 2 Day-Before Regimen

<table>
<thead>
<tr>
<th>Sodium picosulfate, magnesium oxide, and anhydrous citric acid Day-Before Regimen</th>
<th>2 L PEG+E* with 2 × 5-mg bisacodyl tablets</th>
<th>Difference between treatment groups</th>
</tr>
</thead>
<tbody>
<tr>
<td>% (n/N)</td>
<td>% (n/N)</td>
<td>Difference</td>
</tr>
<tr>
<td>83% (244/294)</td>
<td>80% (239/300)</td>
<td>3%</td>
</tr>
</tbody>
</table>

* 2 L PEG + E = two liters polyethylene glycol plus electrolytes solution.
† Non-inferior

16 HOW SUPPLIED/STORAGE AND HANDLING

How Supplied
CLENPIQ is supplied in a carton containing two bottles, each holding 160 mL of cranberry-flavored, colorless to slightly yellow, clear oral solution, along with an eight-ounce cup for measuring fluids for hydration. Each bottle contains 10 mg sodium picosulfate, 3.5 g magnesium oxide, and 12 g anhydrous citric acid.

CLENPIQ Cranberry flavor: NDC# 55566-6700-1.

Storage
Store CLENPIQ at 25°C (77°F). Excursions permitted at 15°C to 30°C (59°F to 86°F). [See USP Controlled Room Temperature]. Do not refrigerate or freeze.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).

Instruct patients:
- CLENPIQ does not need to be diluted prior to administration. One bottle of CLENPIQ is equivalent to one dose.
- Two doses of CLENPIQ are required for a complete preparation for colonoscopy either as a Split-Dose (preferred) or Day-Before dosing regimen. See Instructions for Use.
- Not to take other laxatives while they are taking CLENPIQ.
- Do not eat solid food or dairy and do not drink anything colored red or purple.
- Do not drink alcohol.
- Do not take oral medications within one hour of starting CLENPIQ.
- If taking tetracycline or fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, or penicillamine, take these medications at least 2 hours before and not less than 6 hours after administration of CLENPIQ.
- To follow the directions in the Instructions for Use, for either the Split-Dose or the Day-Before regimen, as prescribed.
- To consume additional fluids after each dose of CLENPIQ.
- To delay the second dose of CLENPIQ, if severe bloating, distention, or abdominal pain occurs following the first dose until the symptoms resolve.
- To contact their healthcare provider if they develop significant vomiting or signs of dehydration after taking CLENPIQ or if they experience altered consciousness (e.g. confusion, delirium, loss of
consciousness) or seizures [see Warnings and Precautions (5.1, 5.2, 5.4)].

Manufactured by:
ASM Aerosol-Service AG
Industriestrasse 11, CH - 4313 Möhlin
Switzerland
Manufactured for:
Ferring Pharmaceuticals Inc.
Parsippany, N.J. 07054
8107000049

MEDICATION GUIDE
CLENPIQ™ (CLEN-pik)
(sodium picosulfate, magnesium oxide, and anhydrous citric acid)
oral solution

Read and understand these Medication Guide instructions at least 2 days before your colonoscopy and again before you start taking CLENPIQ.

What is the most important information I should know about CLENPIQ?
CLENPIQ and other bowel preparations can cause serious side effects, including:
- Serious loss of body fluid (dehydration) and changes in blood salts (electrolytes) in your blood. These changes can cause:
  - abnormal heartbeats that can cause death.
  - seizures. This can happen even if you have never had a seizure.
  - kidney problems.

Your chance of having fluid loss and changes in blood salts with CLENPIQ is higher if you:
- have heart problems
- have kidney problems
- take water pills or non-steroidal anti-inflammatory drugs (NSAIDS)

Tell your healthcare provider right away if you have any of these symptoms of a loss of too much body fluid (dehydration) while taking CLENPIQ:
- vomiting
- urinating less often than normal
- dizziness
- headache

See "What are the possible side effects of CLENPIQ?" for more information about side effects.

What is CLENPIQ?
CLENPIQ is a prescription medicine used by adults to clean the colon before a colonoscopy. CLENPIQ cleans your colon by causing you to have diarrhea. Cleaning your colon helps your healthcare provider see the inside of your colon more clearly during your colonoscopy.

It is not known if CLENPIQ is safe and effective in children.

Do not take CLENPIQ if your healthcare provider has told you that you have:
- serious kidney problems.
- a blockage in your intestine (bowel obstruction).
- an opening in the wall of your stomach or intestines (bowel perforation).
- a very dilated intestine (toxic megacolon).
- problems with the emptying of food and fluid from your stomach (gastric retention).
- an allergy to any of the ingredients in CLENPIQ. See the end of this leaflet for a complete list of ingredients in CLENPIQ.
Before taking CLENPIQ, tell your healthcare provider about all of your medical conditions, including if you:

- have problems with serious loss of body fluid (dehydration) and changes in blood salts (electrolytes).
- have a history of seizures or take medicines for seizures.
- are withdrawing from drinking alcohol or from taking benzodiazepines.
- have low blood salt (sodium) level.
- have kidney problems or take medicines for kidney problems.
- have heart problems.
- have stomach or bowel problems including ulcerative colitis.
- have problems with swallowing or gastric reflux.
- are pregnant. It is not known if CLENPIQ will harm your unborn baby. Talk to your provider if you are pregnant.
- are breastfeeding or plan to breastfeed. It is not known if CLENPIQ passes into your breast milk. You and your healthcare provider should decide if you will take CLENPIQ while breastfeeding.

Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. CLENPIQ may affect how other medicines work. Medicines taken by mouth may not be absorbed properly when taken within 1 hour before the start of CLENPIQ.

Especially tell your healthcare provider if you take:

- medicines for blood pressure or heart problems.
- medicines for kidney problems.
- medicines for seizures.
- water pills (diuretics).
- nonsteroidal anti-inflammatory medicines (pain medicines).
- medicines for depression or mental health problems.
- laxatives. Do not take other laxatives while taking CLENPIQ.

The following medicines should be taken at least 2 hours before starting CLENPIQ and not less than 6 hours after taking CLENPIQ:

- tetracycline
- fluoroquinolone antibiotics
- iron
- digoxin (Lanoxin)
- chlorpromazine
- penicillamine (Cuprimine, Depen)

Ask your healthcare provider or pharmacist for a list of these medicines if you are not sure if you are taking the medicines listed above.

Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

How should I take CLENPIQ?
See the Instructions for Use for dosing instructions. You must read, understand, and follow these instructions to take CLENPIQ the right way.

- Take CLENPIQ exactly as your healthcare provider tells you to take it.
- CLENPIQ comes ready to drink. It does not need to be mixed with anything else.
- 1 bottle of CLENPIQ equals 1 dose. Two doses of CLENPIQ are required for complete colonoscopy preparation.
- There are 2 different methods for taking CLENPIQ. It is better (preferred) to use the Split-Dose method. If you cannot do the Split-Dose method, you can take CLENPIQ using the Day-Before
method. See the instructions for use for more information.

- All people taking CLENPIQ should follow these general instructions starting 1 day before your colonoscopy:
  - only drink clear liquids all day and the next day until 2 hours before your colonoscopy. Stop drinking all fluids at least 2 hours before the colonoscopy.
  - after taking the first dose drink five 8 ounce cups (40 ounces total) of clear liquids using the cup provided within 5 hours.
  - after taking CLENPIQ if you have any bloating or feeling like your stomach is upset, wait to take your second dose until your stomach feels better.

- While taking CLENPIQ, do not:
  - take any other laxatives.
  - take any medicines by mouth (oral) within 1 hour of starting CLENPIQ.
  - eat solid foods, dairy such as milk, or alcohol while taking CLENPIQ and until after your colonoscopy.
  - eat or drink anything colored red or purple.

**Contact your healthcare provider right away** if after taking CLENPIQ you have severe vomiting, signs of dehydration, changes in consciousness such as feeling confused, delirious or fainting (loss of consciousness) or seizures after taking CLENPIQ.

**What are the possible side effects of CLENPIQ?**

CLENPIQ can cause serious side effects, including:

See "What is the most important information I should know about CLENPIQ"?

- **Changes in certain blood tests.** Your healthcare provider may do blood tests after you take CLENPIQ to check your blood for changes. Tell your healthcare provider if you have any symptoms of too much fluid loss, including:
  - vomiting
  - stomach-area (abdomen) cramping
  - seizures
  - nausea
  - urinate less than usual
  - heart problems
  - bloating
  - trouble drinking clear liquids
  - dizziness
  - troubles swallowing

- **Ulcers of the bowel or bowel problems (ischemic colitis).** Tell your healthcare provider right away if you have severe stomach-area (abdomen) pain or rectal bleeding.

The most common side effects of CLENPIQ include:

- nausea
- headache
- vomiting

These are not all the possible side effects of CLENPIQ.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

**How should I store CLENPIQ?**

- Store CLENPIQ at room temperature, between 68 to 77°F (20 to 25°C).

**Keep CLENPIQ and all medicines out of the reach of children.**

**General information about the safe and effective use of CLENPIQ.**

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use CLENPIQ for a condition for which it was not prescribed. Do not give CLENPIQ to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about CLENPIQ that is written for health professionals.

**What are the ingredients in CLENPIQ?**
CLENPIQ comes in a carton containing 2 bottles, along with an 8-ounce cup for measuring fluids for hydration. Each bottle contains:

**Active ingredients:** sodium picosulfate, magnesium oxide, and anhydrous citric acid

**Inactive ingredients:** disodium edetate, sodium benzoate, malic acid, sucralose, acesulfame potassium, sodium metabisulfite, sodium hydroxide, cranberry flavor, and water. The cranberry flavor contains maltodextrin, glyceryl triacetate (triacetin) and sodium octenyl succinated starch.

Manufactured by: Ferring Pharmaceuticals Inc.
Parsippany, NJ 07054, USA
8107000049
11/2017

For more information, go to www.CLENPIQ.com or call 1-888-337-7464.

This Medication Guide has been approved by the U.S. Food and Drug Administration.

**PRINCIPAL DISPLAY PANEL - 10 mg/3.5 g/12 g Bottle Carton**

Cranberry
Flavor
NDC 55566-6700-1

CLENPIQ™
(sodium picosulfate, magnesium oxide, and anhydrous citric acid) Oral Solution

10 mg/3.5 g/12 g per 160 mL bottle

CLENPIQ™ is a ready-to-drink oral solution that doesn't need to be diluted.

Read the inclosed Instructions for Use and Medication Guide AT LEAST 2 DAYS BEFORE your colonoscopy and again right before taking CLENPIQ™.

Contains two (2) 160 mL bottles

Rx only

FERRING
PHARMACEUTICALS
CLENPIQ™ is a ready-to-drink oral solution that doesn’t need to be diluted.

Read the enclosed Instructions for Use and Medication Guide AT LEAST 2 DAYS BEFORE your colonoscopy and again right before taking CLENPIQ™.

Contains two (2) 160 mL bottles

This carton contains:
- Prescribing Information with Medication Guide and Instructions for Use
- Cup to be used for drinking clear liquids after taking CLENPIQ™
- Two (2) 160 mL bottles, each containing:
  - 10 mg sodium picosulfate, USP
  - 3.5 g magnesium oxide, USP
  - 12 g anhydrous citric acid, USP

CLENPIQ™ (sodium picosulfate, magnesium oxide, and anhydrous citric acid) Oral Solution
10 mg/3.5 g/12 g per 160 mL bottle

CLENPIQ™ is a ready-to-drink oral solution that doesn’t need to be diluted.

Read the enclosed Instructions for Use and Medication Guide AT LEAST 2 DAYS BEFORE your colonoscopy and again right before taking CLENPIQ™.

If you have questions about how to take CLENPIQ™, talk to your healthcare provider.

For more information, go to www.clenpiq.com or call 1-888-337-7464.
Keep this and all drugs out of the reach of children.

CLENPIQ
sodium picosulfate, magnesium oxide, and anhydrous citric acid liquid
### Product Information

<table>
<thead>
<tr>
<th>Product Type</th>
<th>HUMAN PRESCRIPTION DRUG</th>
</tr>
</thead>
<tbody>
<tr>
<td>Route of Administration</td>
<td>ORAL</td>
</tr>
<tr>
<td>Item Code (Source)</td>
<td>NDC:72032-6700</td>
</tr>
</tbody>
</table>

### Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>SODIUM PICOSULFATE (UNII: LR57574HN8) (DEACETYLBISACODYL - UNII:R09078E41Y)</td>
<td>SODIUM PICOSULFATE</td>
<td>10 mg in 160 mL</td>
</tr>
<tr>
<td>MAGNESIUM OXIDE (UNII: 3A3U0G771G) (MAGNESIUM CATION - UNII:T6V3LHY838)</td>
<td>MAGNESIUM OXIDE</td>
<td>3.5 g in 160 mL</td>
</tr>
<tr>
<td>ANHYDROUS CITRIC ACID (UNII: XF417D3PSL) (ANHYDROUS CITRIC ACID - UNII:XF417D3PSL)</td>
<td>ANHYDROUS CITRIC ACID</td>
<td>12 g in 160 mL</td>
</tr>
</tbody>
</table>

### Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>EDEDATE DISODIUM (UNII: 7FLD91C86K)</td>
<td></td>
</tr>
<tr>
<td>SODIUM BENZOATE (UNII: O1245FE5EU)</td>
<td></td>
</tr>
<tr>
<td>CRANBERRY (UNII: 0MVO31Q3QS)</td>
<td></td>
</tr>
<tr>
<td>MALIC ACID (UNII: 817L1N4CKP)</td>
<td></td>
</tr>
<tr>
<td>SACRALOSE (UNII: 96K6UQ3ZD4)</td>
<td></td>
</tr>
<tr>
<td>ACESULFAME POTASSIUM (UNII: 230V73Q5G9)</td>
<td></td>
</tr>
<tr>
<td>SODIUM HYDROXIDE (UNII: 55X04QC32I)</td>
<td></td>
</tr>
<tr>
<td>SODIUM METABISULFITE (UNII: 4VON5FNS3C)</td>
<td></td>
</tr>
<tr>
<td>WATER (UNII: 059QF0KO0R)</td>
<td></td>
</tr>
</tbody>
</table>

### Product Characteristics

<table>
<thead>
<tr>
<th>Color</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shape</td>
<td>Size</td>
</tr>
<tr>
<td>Flavor</td>
<td>Imprint Code</td>
</tr>
<tr>
<td>Contains</td>
<td></td>
</tr>
</tbody>
</table>

### Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:72032-6700-1</td>
<td>2 in 1 CARTON</td>
<td>11/28/2017</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>NDC:72032-6700-0</td>
<td>160 mL in 1 BOTTLE; Type 0: Not a Combination Product</td>
<td>11/28/2017</td>
<td></td>
</tr>
</tbody>
</table>

### Marketing Information

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA</td>
<td>NDA209589</td>
<td>11/28/2017</td>
<td></td>
</tr>
</tbody>
</table>

**Labeler** - ASM Aerosol-Service AG (480286111)
## Establishment

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>ID/FEI</th>
<th>Business Operations</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASM Aerosol-Service AG</td>
<td></td>
<td>480286111</td>
<td>MANUFACTURE(72032-6700), PACK(72032-6700), LABEL(72032-6700), ANALYSIS(72032-6700)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>ID/FEI</th>
<th>Business Operations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interlabor</td>
<td></td>
<td>482340957</td>
<td>ANALYSIS(72032-6700)</td>
</tr>
</tbody>
</table>

Revised: 1/2020

ASM Aerosol-Service AG